ClinicalTrials.gg
Active, not recruitingNCT03339115AHEADUpdated Mar 17, 2026

AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System

An interventional study of Cardiovalve Transfemoral Mitral Valve in Mitral Regurgitation and Mitral Valve Disease, sponsored by Cardiovalve Ltd.. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Cardiovalve Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.

Planned enrollment
35th of 48
30 · median 113
Started
2018
with 4 others
No phase
39 of 81
12 open now
Primary completion
2026-12
later than 12 of 31 live
Registered
39th of 81
by date

Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 35th largest by planned enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2018, is one of 39 with no phase, reaches primary completion later than 12 of the 31 other live ones, and was the 39th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Mitral Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

This study will evaluate the safety of the Cardiovalve Transfemoral Mitral Valve System with its associated procedure, and observe the device performance in reducing mitral regurgitation. Data collected in this clinical study will include 30-day safety and performance, and long-term clinical outcomes over a follow-up of 2 years.

Read the detailed description

The Cardiovalve offers a mitral replacement valve delivered through a transfemoral access and transseptal approach, and is intended to reduce mortality and adverse event rates in selected patients for whom surgical options are not feasible.

Innovation: A truly trans femoral, trans venous delivery of the prosthetic mitral valve which minimizes procedural risk. The Cardiovalve Implant features a dual nitinol frame for robust radial strength with decoupling of the atrial flange and ventricular portion which contains 24 grasping legs designed for atraumatic anchoring of the device to the native mitral annulus. Valve leaflets are made of bovine pericardium. The Cardiovalve implant has a very low left ventricle (LV) protrusion footprint thus reducing the risk of LV outflow tract obstruction and/or interference with the LV. The Cardiovalve delivery system (DS) is designed for transfemoral delivery of the Implant with transseptal access to the left atrium. The catheter assembly is used to center the implant relative to the native mitral valve plane and align it with the left ventricual apex-to-base axis. After valve implantation, the delivery system is withdrawn.

03

Conditions studied

  • Mitral Regurgitation
  • Mitral Valve Disease

Keywords

  • Mitral Insufficiency
  • Heart Failure
  • Mitral Valve
  • Heart Diseases
  • Valvular Heart Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria

  1. Age ≥ 18 years
  2. functional II, III or ambulatory IV
  3. Severe mitral regurgitation (MR grade 3-4+)
  4. Subject is on optimal guideline-directed medical therapy for heart failure for at least 30 days or CRT if indicated.
  5. Elevated risk for conventional open mitral valve repair or replacement surgery in the consideration of the site Heart Team (including a cardiac surgeon, a cardiologist and imaging specialist as a minimum) based on STS/Euro Score II (per MVARC Part 1), frailty and co-morbidities.
  6. Able to undergo Transesophageal Echocardiography (TEE).
  7. Subject understands the study requirements and the treatment procedures and provides written before any study-specific tests or procedures are performed.
  8. The subject commits to return for the scheduled post-operative follow-up visits at the hospital.

    Anatomical Inclusion Criteria

  9. Suitable for femoral access procedure and trans septal catheterization
  10. Native mitral valve geometry and size and LV outflow tract characteristics compatible with the Cardiovalve (as assessed by the independent Screening Committee)

Cardiovascular Exclusion Criteria

  1. Prior stroke or within 3 months or Modified Rankin Scale ≥4 disability
  2. Acute myocardial infarction within the previous 30 days
  3. Any prior heart valve surgery or transcatheter mitral intervention
  4. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
  5. Rheumatic heart disease or endocarditis within the previous 3 months
  6. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
  7. Existence of inferior vena cava filter or atrial septal device (contraindicating femoral access and transseptal catheterization)
  8. Untreated coronary artery disease requiring revascularization
  9. Tricuspid valve disease requiring surgery or severe tricuspid regurgitation
  10. Aortic or pulmonic valve disease requiring surgery
  11. CRT/ICD implant within 30 days

    Anatomical Exclusion Criteria (assessed by pre-procedural imaging)

  12. (LVEF) \<30%
  13. LV end diastolic diameter > 70mm
  14. Significant abnormalities of the mitral valve and sub-valvular apparatus.
  15. Severe mitral annular or leaflets calcification
  16. Left atrial or LV thrombus or vegetation
  17. Severe right ventricular dysfunction
  18. Severe tricuspid or aortic valve disease

    General Exclusion Criteria

  19. Subject who is currently participating in an study, other than this study
  20. Hemodynamic instability defined as systolic pressure \< 90mmHg or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device, or any mechanical heart assistance
  21. Subject has contrast agent that cannot be adequately pre-medicated, has an allergy to Nitinol alloys (nickel and titanium), or has intolerance to antiplatelet, anticoagulant, or thrombolytic medications
  22. Bleeding diathesis or hypercoagulable state
  23. Active peptic ulcer or active gastrointestinal bleeding
  24. Pulmonary artery systolic pressure >70 mmHg
  25. Patients with renal insufficiency (creatinine > 2.5 mg/dL)
  26. Need for emergent or urgent surgery for any reason or any planned cardiac Surgery within the next 12 months
  27. Subject with hepatic insufficiency
  28. Subject has a co-morbid illness that may result in a of less than one year
  29. Active infection that requires antibiotic therapy
  30. Subject is pregnant, breastfeeding or intend to become pregnant within one year
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cardiovalve Transfemoral Mitral Valve

    Mitral replacement valve delivered through a transfemoral access and transseptal approach

    Device: Cardiovalve Transfemoral Mitral Valve

Interventions

  • DeviceCardiovalve Transfemoral Mitral Valve

    The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.

06

What researchers measure

Primary outcomes

  1. The primary safety endpoint is freedom from all-cause mortality and major adverse events

    Freedom from all-cause mortality, all cause hospitalization, major adverse cardiac events (MACE), major device- or procedure- related serious adverse events

    Time frame: 30 days, 3 Months, 6 Months, 12 Months, and 24 Months

Secondary outcomes

  1. Technical success

    Technical success: I. Absence of procedural mortality II. Delivery and deployment of the device in the correct position and retrieval of delivery catheter, without significant mitral stenosis, LVOT obstruction or paravalvular MR documented by intraoperative imaging \[Time Frame:Intraoperative\] III. Freedom from emergency surgery or reintervention related to the device or access procedure \[Time Frame: 30 days\]

    Time frame: Intraoperative, 30 Days

  2. Device Success

    I. Absence of procedural mortality or stroke II. Proper placement and positioning of the device III. Freedom from unplanned surgical or interventional procedures related to the device or access procedure

    Time frame: Intraoperative

  3. Device Success

    IV. Continued intended safety and performance of the device including: 1. No evidence of structural or functional failure 2. No specific device-related technical failure issues and complications 3. Reduction in MR grade to either optimal (0+ to trace) or acceptable (reduced by at least 1 grade from baseline with no more than 2+ MR). Number of patients with reduction in MR grade from baseline

    Time frame: 30 days, 3 Months, 6 Months, 12 Months, and 24 Months

  4. Patient Success

    I. Device success (either optimal or acceptable) II. Patient returned to the pre-procedural setting * III. Freedom from rehospitalizations or reinterventions for the underlying condition (e.g., mitral regurgitation, worsening of heart failure) * IV. Improvement from baseline in NYHA functional class Number of patients with improvement in NYHA class * V. Six minute walk test Increase in distance (m) from baseline * VI. Improvement from baseline in quality-of-life (Kansas City Cardiomyopathy Questionnaire improvement by ≥ 10)

    Time frame: 30 days, 3 Months, 6 Months, 12 Months, and 24 Months

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2018 (actual). Primary completion is estimated for Dec 2026, 104 months after the start.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 104 months is above that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2017
First posted
Nov 13, 2017
StartActual
Apr 23, 2018
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2030
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03339115
Lead sponsor
Cardiovalve Ltd.
Collaborators
Meditrial Europe Ltd., Meditrial SrL
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Apr 23, 2018
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 17, 2026

Study contacts

Georg Nickenig
principal investigator · Bonn Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion